Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/27/2010

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, October 31, 2010 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

The following abstracts are available on the AASLD website (AASLD.org).

RG7128Abstract 81"High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study" will be presented in the HCV Clinical Trials session on Sunday October 31st at 5:15pm ET. Authors of the study are Jensen, D. M. et al.

Abstract 799"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study" will be presented in a poster session on Sunday October 31st. Authors of the study are Le Pogam, S. et al.

PSI-7977Abstract 806"High Rapid Virologic Response (RVR) with PSI-7977 Daily Dosing plus PEG-IFN/RBV in a 28-day Phase 2a Trial" will be presented in a poster sessi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Present at the JMP Healthcare Conference
2. Pharmasset to Present at the UBS Global Life Sciences Conference
3. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
4. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2009 Financial Results
6. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
7. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
10. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
11. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
(Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 25, 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. ... the largest retail drugstore chain in China based on ... unaudited financial results for the first quarter ended March ... ended March 31, 2011: Revenue increased by ...
... 24, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... commercialization of products for central nervous system disorders, today announced ... on Thursday, June 16, 2011, in Rockville, Maryland.  The record ... stockholders of record as of the close of business on ...
Cached Medicine Technology:China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 2China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 3China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 4China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 5China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 6China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 7China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 8China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results 9
(Date:4/18/2014)... Three Johns Hopkins University School of Medicine researchers have ... treatments for diabetes, Novo Nordisk announced this month. Of ... Diabetes and Obesity Biologics Science Forum Program, only four ... Johns Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; ... , Jonathan Powell, a professor of oncology, will ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently ... molecule in metastatic breast cancer reduces both the growth ... BRI scientists have found in models of the disease ... - 80 percent and can keep the tumor from ... five-year grant comes from the National Cancer Institute of ...
(Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... river is in the news again, for all the wrong ... York state are warning boaters and others who use the ... million gallons of raw sewage that reached the river after ... health concern would be for anyone coming in contact with ...
... alarm for parents about a common myth: that children dont ... so-called brain attacks each year, and half of them end ... ,Strokes in children may occur even more ... sadly, strokes in children are sometimes not recognized and treated, ...
... a one-year-old child having his foot amputated has moved ... an explanation. ,In January, a fractured leg brought ... his limb was plastered below the waist. However, the skin ... necessitating its surgical separation on March 5. ,A ...
... boys affected by Duchenne muscular dystrophy. A new study has found ... their own for a longer period of time and reduce their ... in 3,500 boys. Symptoms start in early childhood and rapidly progress ... and 11. There is no cure for the disorder. ...
... Former US president Bill Clinton has once again lent a ... fallout between the Brazil government and drug giant Merck ... diffuse the situation. Clinching a deal with two Indian pharmaceutical ... the companies to provide second-line AVR drugs and a next ...
... prescribed a drug that reduces their estrogen levels. But ... is widespread concern about how the estrogen-reducing drugs - ... ,A study at Washington University School of Medicine in ... aromatase inhibitors, and researchers are calling for interested women ...
Cached Medicine News:Health News:Sewage Flows into Hudson River in a Torrent 2Health News:Sewage Flows into Hudson River in a Torrent 3Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:Court Seeks Explanation from Hospital for Childs Amputation 2Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2Health News:Clinton Foundation Eases Over-Pricing Of AIDS Drugs Once More 2Health News:Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: